MorphoSys
- Country
- 🇩🇪Germany
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 524
- Market Cap
- $2.8B
- Website
- http://www.morphosys.de
- Introduction
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 3573
- Registration Number
- NCT04697160
- Locations
- 🇬🇧
MorphoSys Research Site, Westcliff-on-Sea, United Kingdom
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
- Conditions
- DLBCL
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- MorphoSys AG
- Registration Number
- NCT04300803
Lenalidomide Monotherapy in R/R DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 490
- Registration Number
- NCT04150328
- Locations
- 🇪🇸
MorphoSys Research Site, Salamanca, Spain
🇮🇹MorphoSys Research State, Novara, Italy
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 66
- Registration Number
- NCT04134936
- Locations
- 🇪🇸
MorphoSys Research Site, Vitoria-Gasteiz 1009, Spain
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 24
- Registration Number
- NCT02639910
- Locations
- 🇬🇧
Clinical Study Site, Leeds, United Kingdom
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 81
- Registration Number
- NCT02399085
- Locations
- 🇺🇸
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇵🇱Szpital Wojewodzki Nr 1 im. Fryderyka Chopina w Rzeszowie, Rzeszow, Poland
🇺🇸Cancer Care - Torrance Memorial Physician Network, Redondo Beach, California, United States
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Drug: MOR00208 (formerly Xmab5574)
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 22
- Registration Number
- NCT01685021
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Drug: MOR00208 (formerly Xmab 5574)
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 92
- Registration Number
- NCT01685008
- Locations
- 🇪🇸
Morphosys Research Site, Sevilla, Spain
🇪🇸MorphoSys Research Site, Madrid #3, Spain
🇮🇹Morphosys, Genova, Italy
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Biological: MOR103Other: Placebo
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 32
- Registration Number
- NCT01517282
- Locations
- 🇬🇧
Morhosys Investigative Site, Manchester, United Kingdom
🇬🇧MorphoSys Investigative Site, Nottingham, United Kingdom
🇵🇱Morphosys Investigative Site, Poznan, Poland
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: MOR03087 phase 1 dose escalation
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 91
- Registration Number
- NCT01421186
- Locations
- 🇦🇹
AKH (Allgemeines Krankenhaus der Stadt Wien), Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I, Vienna, Austria
🇩🇪Medizinische Klinik II, Abt. Hämatologie, Onkologie,, Tübingen, Germany
🇩🇪Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie, Würzburg, Germany